ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Syndax Announces Orphan Drug Designation Granted to Axatilimab for Treatment of Chronic Graft Versus Host Disease
April 07, 2021Syndax Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to axatilimab, its anti-CSF-1R monoclonal antibody, for the treatment of patients with chronic graft versus host disease (cGVHD). -
Syndax Pharma Gets IND Clearance for Leukemia Treatment
July 12, 2019Will begin Phase 1/2 trial for targeted Menin inhibitor, SNDX-5613, in patients with relapsed/refractory acute leukemias. -
Syndax Announces FDA Clearance of IND Application for Targeted Menin Inhibitor
July 11, 2019Syndax Pharmaceuticals announced the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application to begin a Phase 1/2 trial for SNDX-5613, a targeted Menin inhibitor, in patients with relapsed/refractory (R -
Syndax Announces Immuno-Oncology Clinical Trial Collaboration with AstraZeneca
February 02, 2018Syndax Pharmaceuticals Announces New Clinical Partnership with AstraZeneca
Pharma Sources Insight January 2025
